# Pilot Immunotherapy Trial for Recurrent Malignant Gliomas

> **NCT01550523** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 13 (actual)

## Conditions studied

- Malignant Glioma of Brain

## Interventions

- **DRUG:** IGF-1R/AS ODN
- **DEVICE:** biodiffusion chamber

## Key facts

- **NCT ID:** NCT01550523
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-09
- **Primary completion:** 2013-06-25
- **Final completion:** 2013-06-25
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01550523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01550523, "Pilot Immunotherapy Trial for Recurrent Malignant Gliomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01550523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*